Research & Development

What is AbIMP® Technology?

AbIMP® is a novel discovery platform that utilises monoclonal antibodies as selective inhibitors of previously intractable metzincin protease targets thereby offering new possibilities… Read more »

The ADAMs Family of Sheddases – Emerging Therapeutic Targets

The ADAMs gene family of cellular sheddases are exciting, new therapeutic targets and biomarkers emerging within several clinical arenas. ADAM is an acronym… Read more »

ADAM15, A Novel Target for Anti-angiogenesis Therapy

ADAM15 is a “sheddase” known to promote pathological angiogenesis in models of ocular neovascular disease and whose expression correlates strongly with the progression… Read more »

News

Vasgen Shortlisted to Present at Innovate UK Health & Life Science Investment Showcase

May 4th, 2016

London UK, May 4th 2016: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has been shortlisted to… Read more »

Vasgen Selected for Mayor of London Delegation to BIO International 2015 (15-18 June 2015)

June 1st, 2015

London UK, 1st June 2015: Vasgen Limited (“Vasgen” or “the Company”), a London-based biotech company, reports that it will be attending the BIO… Read more »

Vasgen Receives Grant for US Patent and Advances R&D Operations

February 3rd, 2015

London UK, 3rd February 2015: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that the United States Patent and… Read more »